Weight Loss9 min read·Published July 30, 2026

Cheapest Weight Loss Injections Without Insurance: What Patients Should Compare

A cash-pay guide to brand-name GLP-1s, lower-cost liraglutide options, manufacturer programs, and compounded semaglutide or tirzepatide through licensed care.

ByDr. Marcus Holloway
Clinically reviewed by Dr. Anika Rao
Cheapest Weight Loss Injections Without Insurance: What Patients Should Compare

Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.

See if you qualify →

The cheapest weight loss injection without insurance depends on the medication, pharmacy, coupons, and whether a compounded option is appropriate. Liraglutide options and manufacturer self-pay programs may cost less than brand list prices. At Chia, compounded semaglutide injection starts at $249/month and compounded tirzepatide injection starts at $299/month when clinically appropriate.

How did we rank the cheapest weight loss injections without insurance?

We ranked options by likely cash-pay access, evidence for the active ingredient, FDA-approved use, safety limits, and whether a patient can get licensed follow-up care. Weight loss injections can look cheaper at first, but the monthly total may change once visits, supplies, labs, dose changes, and shipping are included.

  • Evidence: human trials and FDA labels for semaglutide, tirzepatide, and liraglutide.
  • Safety: common side effects, contraindications, and warnings listed in FDA labels.
  • Availability: brand, liraglutide, manufacturer program, pharmacy cash-pay, and compounded routes.
  • Care model: whether a licensed clinician evaluates eligibility and monitors side effects.
  • Cost clarity: whether the option gives a realistic monthly starting point instead of only a coupon teaser.

What is the cheapest weight loss injection without insurance?

There is no single cheapest choice for every patient. Liraglutide injection options may have lower pharmacy cash prices than some brand-name weight-loss injections, while compounded GLP-1 options and manufacturer self-pay programs may be lower than some brand list prices, depending on eligibility and supply.

RankOptionBest forCost notes without insuranceKey limitations
1Liraglutide injection optionsPatients who are clinically eligible and comfortable with a daily injectionMay cost less than some brand-name weight-loss injections because additional liraglutide products can add price competitionDaily injection; weight-loss evidence is for liraglutide 3 mg studied in trials, with nausea and GI side effects common 8
2Manufacturer self-pay or savings programsPatients who meet the program rulesCan lower out-of-pocket costs for some brand medicines, but terms change and restrictions applyNot everyone qualifies; programs may exclude some insurance situations or change over time
3Chia compounded semaglutide injectionPatients seeking licensed online evaluation and 503A pharmacy dispensingPlans currently start at $249/month for compounded semaglutide injectionPrescription requires medical review and is not guaranteed; compounded medications are not FDA-approved
4Chia compounded tirzepatide injectionPatients whose provider considers tirzepatide clinically appropriatePlans currently start at $299/month for compounded tirzepatide injectionPrescription requires medical review and is not guaranteed; compounded medications are not FDA-approved
5Brand-name Wegovy, Zepbound, or Saxenda cash-payPatients using FDA-approved chronic weight-management brandsList prices are often above $1,000/month before discountsPrior authorization, supply, and coupon rules can affect access

Why the lowest advertised price may not be the lowest total monthly cost

A low sticker price may not include a provider visit, follow-up care, injection supplies, shipping, or labs if needed. It may also apply only to a starter period, a specific dose, or a limited coupon. Prices, coupons, pharmacy cash prices, and manufacturer savings programs can change, so verify current terms directly with the pharmacy, manufacturer, or provider.

How much do common weight loss injections cost without insurance?

Brand-name GLP-1 cash prices often cluster around four figures per month before discounts. Wegovy and Zepbound list prices are not the same as what a patient pays, but they show why coupons, self-pay programs, pharmacy comparison, and compounded options matter.

Brand-name Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro cash prices

Wegovy (semaglutide, a GLP-1 receptor agonist; also available as compounded semaglutide via state-licensed 503A compounding pharmacy) is FDA-approved for chronic weight management, with FDA-label titration from 0.25 mg once weekly to maintenance doses listed in the label 1. Zepbound (tirzepatide, a dual GIP/GLP-1 receptor agonist; also available as compounded tirzepatide via state-licensed 503A compounding pharmacy) is FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity, with FDA-label once-weekly dosing strengths described in its label 2.

Saxenda (liraglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management and is injected daily 3. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes; they may be prescribed off-label for weight loss when a clinician determines it is appropriate 4, 5.

Liraglutide and why it may cost less than some brand-name injections

Liraglutide options may cost less than some brand-name weight-loss injections because additional suppliers can compete on price. The trade-off is that liraglutide is a daily injection, and in the SCALE Obesity and Prediabetes trial, liraglutide 3.0 mg was studied with lifestyle changes; nausea, diarrhea, constipation, vomiting, and gallbladder-related events were reported more often than with placebo 8. Individual results vary.

Manufacturer self-pay and savings programs: who may qualify

Some manufacturers offer savings cards or self-pay programs for patients who meet specific rules. These programs can be useful, but they may depend on diagnosis, insurance status, pharmacy channel, and current program terms. Always check the manufacturer page and the dispensing pharmacy before assuming the coupon price applies.

Which injections are FDA-approved for weight loss?

The main FDA-approved injectable medicines for chronic weight management are Wegovy, Zepbound, and Saxenda. Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not chronic weight management, though off-label prescribing can be appropriate after clinician review.

MedicationActive ingredientDrug classFDA-approved useCommon cash-pay routeKey limitations
WegovySemaglutideGLP-1 receptor agonistChronic weight management; label also includes cardiovascular risk reduction in specific adults 1Brand pharmacy cash-pay, savings program, or self-pay channelGI side effects; boxed warning for thyroid C-cell tumors; not for pregnancy
ZepboundTirzepatideDual GIP/GLP-1 receptor agonistChronic weight management and obstructive sleep apnea in adults with obesity 2Brand pharmacy cash-pay, savings program, or self-pay channelGI side effects; boxed warning for thyroid C-cell tumors; not for pregnancy
SaxendaLiraglutideGLP-1 receptor agonistChronic weight management 3Brand cash-pay; other liraglutide products may be availableDaily injection; GI side effects; boxed warning for thyroid C-cell tumors
OzempicSemaglutideGLP-1 receptor agonistType 2 diabetes and cardiovascular risk reduction in certain adults with type 2 diabetes 4Brand cash-pay, if prescribedWeight loss use is off-label; supply and insurance rules may differ
MounjaroTirzepatideDual GIP/GLP-1 receptor agonistType 2 diabetes 5Brand cash-pay, if prescribedWeight loss use is off-label; supply and insurance rules may differ
Compounded semaglutideSemaglutideGLP-1 receptor agonistCompounded medication; not FDA-approvedLicensed provider plus state-licensed 503A compounding pharmacyNo FDA-reviewed outcomes data for the compounded formulation
Compounded tirzepatideTirzepatideDual GIP/GLP-1 receptor agonistCompounded medication; not FDA-approvedLicensed provider plus state-licensed 503A compounding pharmacyNo FDA-reviewed outcomes data for the compounded formulation

Semaglutide, tirzepatide, and liraglutide affect appetite regulation and delayed gastric emptying. They also affect insulin secretion and glucagon reduction, which is why Ozempic and Mounjaro are diabetes medicines and why medical history matters before any prescription 1, 4, 5.

How do semaglutide, tirzepatide, and liraglutide compare for cost and use?

Semaglutide and tirzepatide are once-weekly injections in FDA-approved brand labels, while liraglutide is daily. Tirzepatide and semaglutide have strong weight-loss trial data for the active ingredients, but side effects and contraindications are important, and compounded formulations do not have FDA-reviewed outcomes data.

What works, and what are the trade-offs?

In the STEP 1 trial, adults with overweight or obesity without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention; the mean body-weight change was -14.9% with semaglutide versus -2.4% with placebo at 68 weeks 6. Gastrointestinal side effects were common, and the FDA label warns about risks including pancreatitis, gallbladder disease, kidney injury, and thyroid C-cell tumor risk in people with certain personal or family histories 1. Individual results vary.

In the SURMOUNT-1 trial, adults with obesity or overweight without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly; mean weight change at 72 weeks was -15.0%, -19.5%, and -20.9%, compared with -3.1% with placebo 7. Nausea, diarrhea, and constipation were common, and the FDA label includes warnings similar to other incretin medicines, including thyroid C-cell tumor risk and pancreatitis precautions 2. Individual results vary.

In the SCALE Obesity and Prediabetes trial, liraglutide 3.0 mg daily plus lifestyle counseling led to greater weight loss than placebo at 56 weeks 8. The daily injection schedule can be a drawback, and the label includes warnings about thyroid C-cell tumors, pancreatitis, gallbladder disease, and low blood sugar risk when used with certain diabetes medicines 3.

Why dose, supply, pharmacy, and availability can change the final price

A higher dose, a longer supply, a specific pharmacy network, or a shortage can change what you pay. Prior authorization does not help a cash-pay patient directly, but it can still affect pharmacy workflows and access if a prescription was originally written through an insurance pathway.

Are compounded GLP-1 injections a lower-cost option?

They can be, but they are a different regulatory category from brand-name drugs. Compounded semaglutide and compounded tirzepatide are made for an individual prescription by a licensed compounding pharmacy; they are not FDA-approved medications.

What compounded semaglutide and compounded tirzepatide are

Compounded semaglutide via state-licensed 503A compounding pharmacy and compounded tirzepatide via state-licensed 503A compounding pharmacy are prescription medications prepared by a compounding pharmacy when a licensed clinician determines they are appropriate for a specific patient. Do not describe compounded products as interchangeable generics or FDA-approved copies of Wegovy, Ozempic, Zepbound, or Mounjaro; compounded drugs are not FDA-approved copies of those brands.

What 503A compounding pharmacies do

A 503A compounding pharmacy prepares medications for individual prescriptions under state pharmacy oversight and federal compounding rules. The FDA says compounded drugs can serve patients when an approved product does not meet a medical need, but compounded drugs do not go through FDA premarket review for safety, effectiveness, or quality 9.

Important limits: compounded medications are not FDA-approved

The safety theme is licensed versus unlicensed access. A provider-reviewed prescription filled by a state-licensed 503A pharmacy is not the same as buying a no-prescription “research chemical” online. The FDA has warned patients about unapproved GLP-1 products sold outside normal prescription channels 10.

3-min quiz

Compare GLP-1 options with a licensed provider

Chia offers compounded semaglutide injection from $249/month and compounded tirzepatide injection from $299/month when clinically appropriate. Treatment starts with an online health questionnaire and licensed-provider review; a prescription is not guaranteed. Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality.

Weight loss injections at Chia: compounded semaglutide or tirzepatide

At Chia, we offer a clinician-reviewed cash-pay path for compounded GLP-1 treatment. Two injection options are available in our current catalog: compounded semaglutide injection and compounded tirzepatide injection.

Chia optionForms Chia offersCurrent starting priceMicrodosing plansHow it works
SemaglutideInjectionPlans currently start at $249/monthAvailable when provider-guided and clinically appropriateOnline questionnaire, licensed-provider review, 503A pharmacy compounding, home shipping
TirzepatideTablets and injectionInjection plans currently start at $299/month; tablets from $249/monthAvailable when provider-guided and clinically appropriateOnline questionnaire, licensed-provider review, 503A pharmacy compounding, home shipping

How Chia’s online provider review and home shipping work

You start through the eligibility quiz, then complete a short health questionnaire. A licensed US provider reviews your BMI, medical history, current medicines, contraindications, and goals. If treatment is clinically appropriate, the medication is compounded in the US by a state-licensed 503A pharmacy and shipped to your door.

Microdosing plans at Chia

Microdosing plans are available for semaglutide and tirzepatide when a Chia provider determines that a lower-dose, provider-guided approach is appropriate. Patients can message their care team through the portal between visits. Some patients also discuss support protocols such as Weight + Energy or Weight + Muscle, depending on goals and provider review.

How can you lower the cost of a weight loss injection without insurance?

The best first step is to compare total monthly cost, not just the drug price. Cash price can change by pharmacy and 30-day supply terms, so ask what is included before you choose.

  1. 1Check manufacturer savings or self-pay programs. Read the rules closely, because eligibility can depend on insurance status, diagnosis, and pharmacy channel.
  2. 2Compare cash prices across pharmacies. The same prescription can price differently at different pharmacies.
  3. 3Ask a licensed provider about clinically appropriate alternatives. This may include FDA-approved brand options, liraglutide options, or compounded GLP-1 treatment through a licensed pharmacy.
  4. 4Consider total cost. Include visit fees, labs if needed, supplies, follow-up care, side-effect support, and shipping.
  5. 5Avoid no-prescription peptide or GLP-1 sellers. Prescription review and licensed pharmacy dispensing are key safety checks.

Who may be eligible for prescription weight loss injections?

Eligibility depends on BMI, diagnosis, medical history, current medications, and contraindications. BMI criteria in FDA labels often include obesity or overweight with at least one weight-related condition, but the final decision belongs to the prescribing clinician.

FDA labels for chronic weight-management medicines include adults with obesity, or adults with overweight plus a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes 1, 2, 3. Zepbound’s label also includes obstructive sleep apnea in adults with obesity 2.

A provider also checks for pregnancy, breastfeeding, pancreatitis history, gallbladder disease, kidney problems, stomach-emptying problems, diabetes medicines that can cause low blood sugar, and personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, which are key label warnings for this drug class 1, 2, 3.

What should you ask before choosing the cheapest option?

Cheapest is only useful if the option is legal, clinically appropriate, and supported by follow-up care. Licensed care and a state-licensed pharmacy matter more than a low advertised price.

  • What medication or active ingredient is being prescribed, and for what diagnosis?
  • Is this an FDA-approved medication for my condition, or a compounded medication prepared for my prescription?
  • If compounded, is the pharmacy state-licensed and operating as a 503A pharmacy?
  • What follow-up care is included if nausea, vomiting, constipation, reflux, or dehydration occurs?
  • What happens if supply changes or my dose plan needs to be adjusted?
  • What is the total monthly cost after visits, supplies, labs, shipping, and refills?

FAQ: cheapest weight loss injection without insurance

3-min quiz

Start with a licensed review

If you are comparing weight loss injection costs without insurance, Chia can help you review whether semaglutide, tirzepatide, or another path fits your health history. The online visit is provider-reviewed, prescriptions are not guaranteed, and medications are dispensed through state-licensed 503A pharmacy partners when prescribed.

References

  1. 1.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2024.
  2. 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2024.
  3. 3.U.S. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information. 2023.
  4. 4.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2025.
  5. 5.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2024.
  6. 6.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
  7. 7.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
  8. 8.Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
  9. 9.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers. 2024.
  10. 10.U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. 2025.

About this article

Dr. Marcus HollowayInternal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika RaoEndocrinology, MD

This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.

Get a personalized plan

See if GLP-1 is right for your body.

Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.

Take the 3-min quiz

Keep reading

Back to all guides